LRRK2 (Leucine-Rich Repeat Kinase 2) Parkinson's Disease Fingerprint

The goal of this interventional monocentric study is to identify molecular and clinical markers of LRRK2-related Parkinson's disease through blood markers analysis and deep clinical phenotyping. Patients who meet the inclusion criteria, after signing the informed consent form will be clinically evaluated by a neurologist expert in movement disorders. Eventually, patients will undergo a blood sample collection, a brain MRI, and a high density EEG. All data will be collected using an ad hoc electronic Case Report Form (CRF) developed for the study

Inclusion Criteria: * age 30-80 years, * clinically established diagnosis of PD according to the Movement Disorders Society (MDS) diagnostic criteria, * Hoehn \& Yahr (H\&Y) stage between 1 and 3, * 10 patients with a LRRK2 associated parkinsonism and 10 with sporadic PD tested with a NGS panel and MLPA for PD associated genes, * ability to provide informed consent. Exclusion Criteria: * Active or history of other neurological disorders, * active infectious disease or history within the previous 4 weeks, * continuative therapy (at least 1 week) with NSAIDs or steroids within the previous 12 weeks, * active malignancy, autoinflammatory or autoimmune diseases or history within the previous 3 years; * alcohol or drug abuse or dependence * any contraindication to the execution of the MRI (including claustrophobia).